Why Small Molecules Still Matter in Drug
Discovery & Therapeutics?

Executive Summary

Small‑molecule therapeutics remain the workhorse modality of modern medicine because they can reach intracellular targets, enable oral dosing, scale reproducibly across global Contract Research and Manufacturing Services (CRAMS) networks, and deliver durable commercial returns. Market outlooks project the small‑molecule drug discovery market growing from ~$61B in 2025 to ~$110B by 2032 (8.8% CAGR), with higher scenarios reaching ~$204B by 2035 (7.9% CAGR)—underscoring resilient demand despite the simultaneous rise of peptides and biologics. [1] [2]

Regulatory data reinforce this centrality: the U.S. FDA approved 46 novel drugs in 2025, with ~65% small molecules, continuing their multi‑year dominance in new approvals and illustrating sustained pipeline strength across oncology, immunology, infectious disease, cardiovascular, and CNS indications. [3] [4]

Beyond market size and approvals, small molecules’ chemically defined synthesis drives batch‑to‑batch reproducibility, quality control, and cost efficiency—all of which are pivotal to CRAMS scalability and supply‑chain resilience. By contrast, biologics’ cell‑based processes add variability and cost, narrowing their use where large, extracellular targets or replacement therapies are essential. [5] [6]

Finally, innovation waves (AI‑guided chemistry, PROTACs, molecular glues) are expanding the small‑molecule frontier to once “undruggable” targets while compressing target‑to‑IND timelines—signaling that small molecules are evolving, not receding. [7] [8] [9]

1) Market Context: Current Revenues and 5–10 Year Outlook

Multiple independent analyses indicate robust and durable growth for small‑molecule discovery:

Coherent Market Insights (2025–2032): $61.04B (2025) → $110.23B (2032); 8.8% CAGR. Drivers: chronic disease prevalence, R&D intensity, and platforms that expedite hit‑to‑lead and optimization. [10]
Precedence Research (2026–2035): $95.63B (2025) → $204.06B (2035); 7.87% CAGR. Notes leadership by small‑molecule segment and North American dominance, with APAC fastest growth. [11]
Mordor Intelligence (2026–2031): $67.4B (2026) → $103.1B (2031); 8.86% CAGR; also highlights that >half of novel FDA approvals in 2025 were small molecules, reflecting modality resilience. [12]

At the macro level, the IQVIA Institute projects global medicine spending to ~$2.3T by 2028, with oncology and immunology as key growth drivers—therapeutic areas where small molecules remain pivotal (alone or in combinations). [13] [14]

Regulatory signal: In 2025, the FDA’s CDER cleared 46 novel drugs, and multiple independent tallies show ~65% were small molecules, up from ~56% in 2023–2024—reaffirming sustained productivity in chemistry‑led pipelines. [15] [16]

Implication: Even as biologics’ revenue share grows due to price/mix, small molecules’ unit volume, breadth of indications, and approval share demonstrate durable strategic importance. [17]

2) Therapeutic Advantages vs. Peptides and Large Molecules

Intracellular Reach. Small molecules (typically <1 kDa) penetrate cell membranes to modulate intracellular enzymes, transcription factors, and nuclear receptors—target space generally inaccessible to biologics constrained to extracellular or cell‑surface interactions. [18]

Oral Dosing & Stability. Many small molecules are orally bioavailable, chemically stable, and ambient‑storage compatible, simplifying logistics, improving adherence, and lowering total‑system costs compared with peptides/biologics that often require injections and cold chain. [19]

CMC Predictability & Reproducibility. Chemical synthesis allows precise structural definition, robust analytics, and consistent scale‑up, while biologics’ living‑cell systems introduce higher process variability and complex characterization requirements. [20]

Clinical Breadth. Oncology retains the largest small‑molecule discovery share (~31.6% in 2025), and CNS pipelines are expanding (leveraging BBB‑penetrant chemotypes). Cardiometabolic and respiratory programs continue to see steady chemistry‑driven innovation. [21] [22]

Recent approvals evidence. In 2025, CDER’s small‑molecule approvals included first‑in‑class NaV1.8 inhibitor for acute pain, novel anti‑infectives (including oral agents for gonorrhea), and precision‑oncology TKIs—underscoring modality versatility across high‑value indications. [23]

3) CRAMS/ CDMO Lens: Reproducibility, Cost, and Global Scalability

Why CRAMS prefer small molecules:

Reproducible Synthesis: Well‑characterized synthetic routes and standardized analytical controls (HPLC, NMR, MS) drive batch‑to‑batch consistency—essential for global tech transfer and multi‑site manufacturing. [24]
Cost & Cycle Time: Chemical routes often enable lower cost of goods and faster scale‑up than cell‑based biologics processes; continuous processing and automation further compress timelines. [25]
Network Capacity: APIs and oral solid dose manufacturing are widely distributed across North America, Europe, and Asia, supporting dual‑sourcing and risk‑mitigation. Major providers continue to invest in HPAPI, continuous flow, and linker‑payload capabilities relevant to modern small‑molecule programs. [26]

Market size & growth. Estimates place the small‑molecule CDMO market in the $70–80B+ range mid‑decade, with trajectories to $120B+ by early‑2030s, reflecting higher outsourcing penetration and consolidation. [27] [28]

Operational takeaway: For sponsors, small molecules provide scalable, reproducible supply across geographies with tighter cost control, which is critical for launch readiness, tender participation, and lifecycle management. [29]

4) Innovation Frontier: AI Chemistry, PROTACs & Molecular Glues

AI‑accelerated discovery. Analyses indicate AI‑native workflows can compress target‑to‑IND by up to ~40% by optimizing hit finding, property prediction, and design‑make‑test cycles—benefiting small molecules’ already‑fast chemistry iteration loops. [30]

Targeted Protein Degradation (TPD). Small‑molecule PROTACs and molecular glues use chemically induced proximity to degrade or reprogram disease drivers, expanding the druggable proteome to “undruggable” targets. Reviews in 2024–2026 document tens of clinical‑stage degraders, optimization principles (e.g., linker design), and growing evidence of oral degraders. [31] [32] [33]

Industry momentum. Pharma and biotech pipelines increasingly include degraders (e.g., ER, AR, MDM2), with oncology leading early applications and immunology/neuroscience emerging—suggesting next‑gen small‑molecule waves will continue to fuel approvals and revenue. [34] [35]

5) Risk Factors and Where Large Molecules Lead

When biologics/peptides win: replacement therapies (e.g., enzymes, hormones), extracellular targets requiring high‑specificity protein interactions, and immune‑engaging mechanisms can favor large molecules. [36]

Headwinds to monitor: resistance mechanisms (e.g., target mutations), safety margins for highly potent chemotypes, and payer dynamics as biosimilars and generics reshape budgets. Macro forecasts still show medicine spending growth through 2028–2029, but with regional variability and LOE (loss of exclusivity) pressures across both biologics and small molecules. [37] [38]

6) Strategic Recommendations for Sponsors & Investors

Modality‑to‑Biology Fit: Prioritize small molecules for intracellular targets and oral‑first strategies; pair with biologics where extracellular modulation or protein replacement is necessary. [39] [40]
Exploit CRAMS Economics: Lock in dual‑site API and drug‑product options early, leverage continuous flow/automation, and align analytical methods across sites to ensure reproducibility and regulatory agility. [41] [42]
Bet on New Chemistries: Build a TPD and molecular glue option set in target reviews; use AI to accelerate DMTA cycles and de‑risk ADME/PK liabilities earlier. [43] [44] [45]
Launch Readiness: Use 2025 FDA approvals patterns (65% small molecules) to calibrate resource mix for CMC, labeling, and medical affairs; anticipate competition from fast‑followers enabled by CRAMS. [46]
Portfolio Resilience: Balance first‑in‑class (novel mechanisms) with best‑in‑class (chemistry refinements) to diversify risk and sharpen payer value propositions. (Context: 2025 approvals included multiple first‑in‑class small molecules across pain, anti‑infectives, oncology.) [47]

Appendix A — Selected 2025 FDA Small‑Molecule Approvals (Illustrative)

Suzetrigine (NaV1.8 inhibitor) for acute pain—first‑in‑class, demonstrating small molecules’ continued innovation in neuromodulation. [48]
Gepotidacin and Zoliflodacin—new oral anti‑infectives addressing resistance and access challenges. [49]
Multiple precision‑oncology TKIs and enzyme inhibitors, reflecting chemistry’s ability to tune selectivity and resistance profiles across tumor subtypes. [50]

Appendix B — Notes on Methodology and Sources

This white paper triangulates regulatory (FDA/CDER) and market sources to present a balanced view:

Regulatory/Approvals: FDA CDER’s official 2025 novel drug approvals list and third‑party analyses summarizing modality mix. [51] [52]
Market Sizing: Independent research firms (multiple vantage points to provide range‑bound projections). [53] [54] [55] [56]
CRAMS/CDMO Dynamics: Industry reports and operator perspectives on reproducibility, cost, consolidation, and technology upgrades. [57] [58] [59]
Modalities & Mechanisms: Peer‑reviewed reviews and industry collections on PROTACs/molecular glues; modality comparisons across size, delivery, and manufacturing complexity. [60] [61] [62] [63]

References (annotated)

FDA – Novel Drug Approvals 2025. Official CDER list and annual report (46 approvals). [FDA page] [64]
C&EN (ACS). “FDA’s new drug approvals dipped in 2025” — overview and 65% small‑molecule share. [65]
Nature (2026). 2025 FDA approvals analysis (context, mix). [66]
Coherent Market Insights (2025). Small‑Molecule Drug Discovery Market: $61.04B → $110.23B (2025–2032; 8.8% CAGR). [67]
Precedence Research (2026). Small‑Molecule Drug Discovery Market: $95.63B (2025) → $204.06B (2035; 7.87% CAGR). [68]
Mordor Intelligence (2026). Market size $67.4B (2026) → $103.1B (2031; 8.86% CAGR); note on >half small‑molecule approvals in 2025; oncology share ~31.6%. [69]
IQVIA Institute (2024/2025). Global medicine spending to ~$2.3T by 2028; R&D momentum and launch productivity trends. [70] [71] [72]
Pharmacy Times (2024). Therapeutic area spending outlook and LOE impacts through 2028. [73]
ScienceInsights (2025). Modality fundamentals (size, intracellular reach, manufacturing reproducibility). [74]
Syner‑G BioPharma (2026). Oral delivery, stability, and cost/logistics advantages of small molecules. [75]
Outsourced Pharma (2025). Small‑molecule CDMO consolidation, capacity, and continuous processing trends. [76]
PharmaSource (2026). Small‑molecule CDMO market overview and growth outlook (Grand View cited). [77]
MilliporeSigma CTDMO (2026). Capabilities in HPAPI, continuous flow, and global scaling for small molecules. [78]
AACR Collection (2026). Advances in PROTACs and molecular glues; expanding druggable targets. [79]
Nature Reviews Chemistry (2025). PROTAC medicinal chemistry lessons and clinical progress. [80]
Cell Press iScience (2024). Molecular glues and TPD modalities overview. [81]